NCCN Guidelines for Patients® | Melanoma

98 NCCN Guidelines for Patients ® : Melanoma, 2018 Index Index ablative therapy 67–68 adjuvant treatment 39, 40–42, 55–56, 60–63, 66–71 biochemotherapy 60–61, 69, 71 biopsy 20–24, 26, 29, 33, 36–38, 52–56, 58–60, 64–66, 73 cancer stage 29, 34, 68, 78 chemotherapy 40, 44–45, 49–50, 60–62, 68, 71 clinical stage 29, 32, 53–61 clinical trial 39, 44, 48–50, 60, 65, 68, 70, 73, 75, 79 dermis 8–10, 12, 17, 20–21, 32, 34, 54, 64 epidermis 8–12, 17, 20, 30, 32, 34, 54, 64 imaging test 24–26, 29, 31, 37, 54, 56–59, 61–63, 65, 68, 71, 73–75 immunotherapy 40–43, 47, 49–50, 60, 62, 70–72, 74–75 in situ 32, 34, 36, 53, 54–57 in-transit 10, 46, 58–68 local melanoma 34, 54–55, 57 local therapy 40, 42–43, 60–63, 66–67, 69 lymph node 10–11, 19, 24–27, 29, 31–34, 36–38, 40–41, 43, 46, 53–54, 56–66, 68–71, 73, 75 lymph node dissection 26, 36–38, 56, 60–61, 68, 70 metastases 21, 31–32, 46, 57, 60–62, 72–75 metastatic melanoma 34, 39, 43, 46, 58, 64, 68, 71–73, 75 NCCN Member Institutions 96 NCCN Panel Members 95 palliative 44, 46, 60, 62, 67–70, 72, 75 pathologic stage 29, 56, 58, 60, 66 pathology report 21–22, 24, 52–53, 78 persistent melanoma 57–58, 64–65 prevention 15–16 primary treatment 39–40, 55–56, 60–62, 69 radiation therapy 46, 50, 56, 70–71, 74, 61, 68–69, 72 recurrence 32, 40, 43, 46, 55–58, 60, 62–71, 73, 75 regional melanoma 34, 46, 58, 60–63 regional therapy 40, 44–45, 61–63, 66–68 risk factor 15, 19, 52–54 satellite 10, 23, 32, 46, 58–59, 60–68 sentinel lymph node biopsy 24, 26, 37–38, 54, 56, 58, 60, 66 side effect 21, 24–25, 37–38, 41–42, 44–49, 70–71, 75, 79 skin biopsy 20, 24, 29, 36, 52–53, 64–65 staging 22, 29, 32–34, 55, 58–59, 65, 71, 73

RkJQdWJsaXNoZXIy MTE3MTE1